The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Can the stock price increases continue, or has the stock set itself up for a pullback?

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

D-Wave Quantum (NYSE: QBTS) calls itself "a leader in the development and delivery of quantum computing systems, software, and services." Investors seem to agree. Since the start of 2025, D-Wave stock ...

The long winter for biotech stocks is over as shares head to levels not seen since late 2021.

The company aims to be an early mover in a potentially transformational opportunity.

It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 ...

Monday is the first day of J.P. Morgan’s annual healthcare investor conference.

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...